Literature DB >> 9393806

Induction of neutrophil chemoattractant cytokines by Mycoplasma hominis in alveolar type II cells.

T Kruger1, J Baier.   

Abstract

Bronchopulmonary dysplasia (BPD) is a chronic lung disease of premature infants who are mechanically ventilated due to respiratory distress. The disease consists of an initial inflammatory influx of neutrophils to the lungs, followed by long-term chronic fibrosis of the lung tissue. The antigenic repertoire that initiates the inflammatory component of BPD has not been defined. Furthermore, the repertoire of cytokines responsible for attracting neutrophils to the lung and the mediators of pathogenesis in BPD have not been characterized. Mycoplasmas such as Mycoplasma hominis and Ureaplasma urealyticum have been isolated from the lungs of infants that developed BPD and yet have not been widely recognized as potential initiators of the inflammatory component of BPD. In the studies described here, we examined the ability of both viable and heat-killed Mycoplasma hominis to elicit type II epithelial cell production of cytokines that are chemotactic for polymorphonuclear leukocytes (PMNs), particularly interleukin-8 (IL-8) and epithelial cell-derived neutrophil-activating peptide (ENA-78). The results of these studies demonstrate that M. hominis and M. hominis antigen are potent stimulators of type II epithelial cell-derived IL-8 and ENA-78. Thus, these data strongly suggest that the presence of M. hominis in the lungs of premature infants may initiate the inflammatory component of BPD by inducing epithelial cell production of cytokines chemotactic for PMNs. Furthermore, these data suggest that the onset of the inflammatory component of BPD likely precedes, and is independent of, the recruitment and activation of alveolar macrophages.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9393806      PMCID: PMC175739          DOI: 10.1128/iai.65.12.5131-5136.1997

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  24 in total

1.  Association of Ureaplasma urealyticum infection of the lower respiratory tract with chronic lung disease and death in very-low-birth-weight infants.

Authors:  G H Cassell; K B Waites; D T Crouse; P T Rudd; K C Canupp; S Stagno; G R Cutter
Journal:  Lancet       Date:  1988-07-30       Impact factor: 79.321

2.  Interleukin-8 in pulmonary effluent fluid of preterm infants.

Authors:  P Groneck; C P Speer
Journal:  J Pediatr       Date:  1993-11       Impact factor: 4.406

3.  Interleukin-8 in bronchoalveolar lavage samples as predictor of chronic lung disease in premature infants.

Authors:  J R McColm; N McIntosh
Journal:  Lancet       Date:  1994-03-19       Impact factor: 79.321

4.  Alveolar macrophages in perinatal infants.

Authors:  E Alenghat; J R Esterly
Journal:  Pediatrics       Date:  1984-08       Impact factor: 7.124

5.  Newborn tracheal aspirate cytology: classification during respiratory distress syndrome and bronchopulmonary dysplasia.

Authors:  T A Merritt; I D Stuard; J Puccia; B Wood; D K Edwards; J Finkelstein; D L Shapiro
Journal:  J Pediatr       Date:  1981-06       Impact factor: 4.406

6.  Role of Ureaplasma urealyticum and other pathogens in the development of chronic lung disease of prematurity.

Authors:  E E Wang; H Frayha; J Watts; O Hammerberg; M A Chernesky; J B Mahony; G H Cassell
Journal:  Pediatr Infect Dis J       Date:  1988-08       Impact factor: 2.129

7.  Association of pulmonary inflammation and increased microvascular permeability during the development of bronchopulmonary dysplasia: a sequential analysis of inflammatory mediators in respiratory fluids of high-risk preterm neonates.

Authors:  P Groneck; B Götze-Speer; M Oppermann; H Eiffert; C P Speer
Journal:  Pediatrics       Date:  1994-05       Impact factor: 7.124

8.  Tumor necrosis factor-induced interleukin-8 expression in cultured human airway epithelial cells.

Authors:  O J Kwon; B T Au; P D Collins; I M Adcock; J C Mak; R R Robbins; K F Chung; P J Barnes
Journal:  Am J Physiol       Date:  1994-10

9.  Interleukin-8, interleukin-6, and soluble tumour necrosis factor receptor type I release from a human pulmonary epithelial cell line (A549) exposed to respiratory syncytial virus.

Authors:  R Arnold; B Humbert; H Werchau; H Gallati; W König
Journal:  Immunology       Date:  1994-05       Impact factor: 7.397

10.  Increased intrahepatic messenger RNA expression of interleukins 2, 6, and 8 in human cirrhosis.

Authors:  J Napoli; G A Bishop; G W McCaughan
Journal:  Gastroenterology       Date:  1994-09       Impact factor: 22.682

View more
  6 in total

Review 1.  Inflammatory mediators in the immunobiology of bronchopulmonary dysplasia.

Authors:  Rita M Ryan; Qadeer Ahmed; Satyan Lakshminrusimha
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 8.667

2.  Nitrite reductase from Pseudomonas aeruginosa released by antimicrobial agents and complement induces interleukin-8 production in bronchial epithelial cells.

Authors:  B Sar; K Oishi; A Wada; T Hirayama; K Matsushima; T Nagatake
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

3.  Activation of nuclear factor kappaB and induction of inducible nitric oxide synthase by Ureaplasma urealyticum in macrophages.

Authors:  Y H Li; Z Q Yan; J S Jensen; K Tullus; A Brauner
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

4.  Involvement of mitogen-activated protein kinase pathways in interleukin-8 production by human monocytes and polymorphonuclear cells stimulated with lipopolysaccharide or Mycoplasma fermentans membrane lipoproteins.

Authors:  C Marie; S Roman-Roman; G Rawadi
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

5.  Activation of macrophage nuclear factor-kappa B and induction of inducible nitric oxide synthase by LPS.

Authors:  Ying-Hua Li; Zhong-Qun Yan; Annelie Brauner; Kjell Tullus
Journal:  Respir Res       Date:  2002-09-05

6.  The Role of Lipoproteins in Mycoplasma-Mediated Immunomodulation.

Authors:  Alexei Christodoulides; Neha Gupta; Vahe Yacoubian; Neil Maithel; Jordan Parker; Theodoros Kelesidis
Journal:  Front Microbiol       Date:  2018-07-31       Impact factor: 6.064

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.